Company intelligence / Profile preview

Merlin BioMed

Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Lead program MER-101 is a preclinical mRNA therapy expressing USP6, showing in vivo efficacy in mouse models by activating anti-cancer immune responses; IND-enabling work planned with goal to enter clinical trials.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugs
Industry: Biotech

Partnerships

Baruch S. Blumberg Institute

Beyond the preview

Go deeper on Merlin BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merlin BioMed.

Explore the full profile